Core Viewpoint - The announcement highlights a long-term global strategic collaboration and licensing agreement between the company and Bristol-Myers Squibb to jointly develop next-generation multispecific antibody therapies [1] Group 1: Partnership Details - The company will collaborate with Bristol-Myers Squibb to advance and accelerate multispecific antibody discovery projects [1] - The agreement includes an upfront payment of $90 million to the company [1] - If Bristol-Myers Squibb decides to pursue all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties based on future product net sales [1]

Core Viewpoint - Heptares Therapeutics has announced a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation multispecific antibody therapies [1] Group 1: Financial Terms - Heptares Therapeutics will receive a total payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, Heptares could receive up to $1.035 billion in development and commercial milestone payments [1] - Additionally, Heptares will earn tiered royalties based on future product net sales [1] Group 2: Market Reaction - Following the announcement, Heptares' stock opened slightly higher but subsequently declined, experiencing a drop of over 5% at one point [1] - As of the latest update, the stock is down 2.08%, trading at HKD 12.72, with a trading volume of HKD 36.45 million [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has entered into a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation bispecific antibody therapies [1] Group 1: Financial Aspects - HAPO Pharmaceuticals will receive a total payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, HAPO Pharmaceuticals could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties based on future product net sales [1] Group 2: Market Reaction - Following the announcement, HAPO Pharmaceuticals experienced a slight increase at the opening but subsequently declined, with a drop exceeding 5% at one point, and currently showing a decrease of 2.08%, trading at HKD 12.72 with a transaction volume of HKD 36.4509 million [1]

Core Viewpoint - The collaboration between Harbour BioMed and Bristol-Myers Squibb marks a significant step in advancing next-generation bispecific antibody therapies, with potential payments exceeding $1.1 billion for Harbour BioMed [2][3]. Group 1: Strategic Collaboration - Harbour BioMed has entered a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation bispecific antibody therapies [1][2]. - The agreement includes an initial payment of $90 million, with potential milestone payments of up to $1.035 billion, plus tiered royalties based on future product net sales [2][3]. Group 2: Technological Advancements - The collaboration will leverage Harbour BioMed's Harbour Mice fully human antibody technology platform, which is capable of efficiently discovering and developing innovative biotherapies [2][3]. - Harbour Mice can generate fully human monoclonal antibodies in various formats, including dual heavy and light chains (H2L2) and heavy chain-only (HCAb) antibodies, enhancing anti-tumor efficacy beyond traditional therapies [3]. Group 3: AI Integration - Harbour BioMed is integrating AI technology into its drug discovery processes, exemplified by the launch of its AI-assisted drug discovery engine, Hu-mAtrIx, which aims to accelerate antibody discovery across multiple therapeutic areas [4]. - The Hu-mAtrIx platform has been designed to work seamlessly with the Harbour Mice technology, utilizing advanced AI models for sequence generation and drugability prediction [4]. Group 4: Global Ecosystem Development - Harbour BioMed has established collaborations with multiple multinational pharmaceutical companies, including AstraZeneca, Pfizer, and Moderna, with total agreements exceeding $10 billion [6][7]. - The company employs diverse collaboration models, including licensing agreements and joint ventures, to enhance its global ecosystem for antibody drug development [7]. Group 5: Future Goals - Harbour BioMed aims to become a "new infrastructure" for global antibody drug development within the next two years, driven by its technological advancements and collaborative efforts [4].

Core Viewpoint - The article discusses a strategic global collaboration and licensing agreement between the company and Bristol-Myers Squibb aimed at discovering and developing a new generation of bispecific antibodies [1] Group 1: Agreement Details - The agreement was established on December 17, 2025, and focuses on the discovery and acceleration of bispecific antibodies [1] - The company will receive an upfront payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]

Core Viewpoint - The announcement highlights a strategic global collaboration and licensing agreement between the company and Bristol-Myers Squibb aimed at discovering and developing next-generation bispecific antibodies [1] Group 1: Agreement Details - The agreement was signed on December 17, 2025, and focuses on the discovery and acceleration of bispecific antibodies [1] - The company will receive an upfront payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]

Core Viewpoint - The announcement highlights a strategic global collaboration and licensing agreement between the company and Bristol-Myers Squibb aimed at discovering and developing next-generation bispecific antibodies [1] Group 1: Agreement Details - The agreement was established on December 17, 2025, and focuses on the discovery and acceleration of bispecific antibodies [1] - The company will receive a total payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb decides to advance all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]

Core Viewpoint - The announcement highlights a strategic collaboration between Heptares Therapeutics-B (02142.HK) and Bristol-Myers Squibb aimed at discovering and developing next-generation multispecific antibodies, with significant financial implications for Heptares [1] Group 1: Partnership Details - Heptares Therapeutics has entered into a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb [1] - The collaboration focuses on the discovery and acceleration of multispecific antibodies [1] Group 2: Financial Implications - Heptares Therapeutics will receive an upfront payment totaling $90 million [1] - If Bristol-Myers Squibb chooses to advance all potential projects, Heptares could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]

Core Insights - Harbour BioMed has entered a multi-year global strategic collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies [1][2] - The agreement includes potential payments totaling $90 million and up to $1.035 billion in development and commercial milestones, along with tiered royalties [2] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company aims to build a robust portfolio through internal R&D, collaborations, and selective acquisitions [4] Technology and Innovation - The proprietary Harbour Mice technology platform generates fully human monoclonal antibodies in various formats, enhancing the therapeutic potential of biologics [5] - The HCAb-based immune cell engagers (HBICE) technology allows for tumor-killing effects that traditional therapies cannot achieve, making the antibody discovery engine unique and efficient [5] Strategic Collaboration - The collaboration with Bristol Myers Squibb is expected to leverage Harbour BioMed's technology and development capabilities, particularly in conducting early clinical trials in China [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由和鉑醫藥控股有限公司（「本公司」或「和鉑醫藥」，連同其附屬公司統稱 「本集團」）自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務更 新。 本公司董事會（「董事會」）欣然宣佈，於2025年12月17日，本公司與百時美施貴 寶已訂立多年全球戰略合作及授權協議（「協議」），旨在發現及開發新一代多特異 性抗體。 根據協議條款，和鉑醫藥將與百時美施貴寶合作，推進及加速多特異性抗體的發 現。作為回報，和鉑醫藥會收到一筆總額為90百萬美元的付款，倘百時美施貴寶 選擇推進所有潛在項目，公司還可獲得最高達1,035百萬美元的開發及商業里程碑 付款以及分級特許權使用費。 警示聲明 我們無法保證我們或合作夥伴將能成功開發或最終銷售本公告所提述的任何候選 產品。本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司 ...